Introduction
============

Body mass index (BMI), as an internationally recognized indicator, provides a simple numeric measure of a person\'s thickness or thinness [@B1]. It is allowing researchers to discuss weight problems more objectively. For a long time, people pay more attention to the relationship between obesity and disease. Many studies have confirmed that obesity is related to the occurrence and prognosis of breast cancer [@B2]-[@B4]. The current mainstream view in the field of breast cancer research is that obesity will increase the incidence of breast cancer, and affect the survival of postmenopausal women with breast cancer [@B5], [@B6]. Although weight control can reduce some of the health problems caused by obesity, few people understand the impact of underweight (BMI\<18.5 kg/m^2^) on health. On the other hand, in today\'s society there is a trend that more and more women, especially young women, to pursue slim or even excessive weight loss for beauty. Meanwhile, underweight remains a severe public health problem especially in south Asian and central and east Africa [@B7]. In 2014, the prevalence of underweight in women in South Asian countries was still 24.0% [@B8]. Breast cancer is the highest incidence of malignant tumors all over the world amongst women [@B9], [@B10]. It is meaningful to explore the relation of low body mass index to the prognosis of breast cancer. However, in contrast to the considerable body of work on obesity, the impact of being underweight on breast cancer has not been adequately addressed. Although it is not documented that being underweight increases the risk of breast cancer [@B11], Marret et al. provided data concerning the possibility that low body mass index may be related to local recurrence of breast cancer after conservative treatment [@B12]. Meanwhile, several studies have reported that underweight populations should be considered as a risk factor for recurrence and overall mortality of breast cancer compared with those of normal weight [@B13]-[@B15]. Although those previous evidences suggest that low body mass index may be related poor prognosis in breast cancer, it is worth reminding that it may not apply to all groups and subtypes. Therefore, there are still many questions about low body mass index in breast cancer worth further discussion. For instance, the proportion of low body mass index in different age groups and whether low body mass index affects breast cancer patients of different ages are still worth a step closer study.

In this study, our objective was to elucidate above issues to some extent. World Health Organization criteria were used to define BMI categories. We collected over ten years of breast cancer patient data from the largest cancer center in southern China. A total of 3891 patients with stage I-IV breast cancer diagnosed between 2001 and 2011 were included to explore the distribution of low BMI in different age groups and prognosis influences.

Patients and methods
====================

Study population
----------------

Female patients who diagnosed with breast cancer and received treatment in Sun Yat-sen University Cancer Center between January 1, 2001 and December 31, 2011 were retrospectively studied. A total of 3891 patients were identified based on the following conditions: female patients diagnosed with invasive carcinoma with data on body mass index and treatment information. Patients with history of other cancers were excluded. Written informed consent was obtained from each patient upon admission to hospital. Patient\'s characteristics and clinical features were collected from the electronic medical record system. The pathologic TNM stage was determined according to the American Joint Committee on Cancer Classification, 7th edition (<http://www.cancerstaging.org>). Estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2) were evaluated by immunohistochemistry. ER positive or PR positive when 1% or more of the cells stained positive. HER-2 positive was defined with immunohistochemical scores of 3+. This study was conducted in accordance with Helsinki declaration and approved by the Institute Research Ethics Committee of Sun Yat-sen University Cancer Center.

Follow-up and endpoints
-----------------------

All patients were subjected to a follow-up program that included outpatient visits or telephone interviews every 3 to 6 months. The last follow-up date to confirm the final conditions was 7 April 2017. Prognosis was evaluated based on disease-free survival (DFS) and overall survival (OS). Death resulting from causes other than breast cancer was treated as censored.

Statistical analyses
--------------------

Patients were divided into two different age groups: Young (18-40 years), Middle and Old (over 40 years). Underweight (UW; BMI\<18.5 kg/m^2^), normal weight (NW; BMI =18.5-24.9 kg/m^2^) and overweight or obese (OW; BMI≥25 kg/m^2^) defined by World Health Organization criteria. All statistical analyses were performed using the Statistical Product and Service Solutions version 23.0 (SPSS, Chicago, IL). The Chi-Square test and Fisher\'s exact test were used to compare characteristics of each group. Log-rank test were used to analyze the differences between survival curves. Cox univariate model, the Hazard Ratio (HR) and the 95% confidence intervals (95% CI) were estimated for variables. Multivariate analysis was performed the variables that were found to be significant in univariate analysis by using stepwise regression (forward selection). Statistical significance was set at *P* \< 0.05.

Results
=======

Clinicopathologic features of BMI groups
----------------------------------------

The median age for the 3891 enrolled patients was 48 (range: 18-92) years old. Their median follow-up time was 81 months (range, 1-197 months \[censored\]). Due to a long diagnosis time span and diverse TNM stages, patients received a great diversity of treatment modalities. Paclitexal-based combination chemotherapy, FEC (uorouracil/epirubicin/cyclophosphamide), CMF (cyclophosphamide/methotrexate/fluorouracil), EC (epirubicin/cyclophosphamide) and CAF/FAC (cyclophosphamide/doxorubicin/fluorouracil) were the main chemotherapy regimens [@B16]. Of the 3891 patients included in this analysis, 616 (15.8%) patients have died and 624 (16.0%) patients have experienced a recurrence. As shown in Fig. [1](#F1){ref-type="fig"}A, the majority of patients in our study are less than 60 years\' old (18-40years 22%, 40-60years 65% and over 60years 13%). Among those patients, about 7% patients suffer from underweight problem and 25% patients suffer from overweight problem when they underwent diagnosis of breast cancer (Fig. [1](#F1){ref-type="fig"}B). We found that weight problems are not the same in different age groups of patients. Underweight problems are mainly found in young patients, while overweight problems are getting worse with age (Fig. [1](#F1){ref-type="fig"}C). Meanwhile, body mass index classification showed a significant association with various prognostic factors such as age (*P*\<0.001), menopause (*P*\<0.001), tumor status (*P*\<0.001), TNM staging (*P*=0.026) and histological grade (*P*=0.043) (Table [1](#T1){ref-type="table"}). Furthermore, we investigated the relationship between BMI groups and clinicopathologic features in different ages groups (Table [2](#T2){ref-type="table"}). We found that the results in the different age groups are different. In young age group, BMI classification showed a significant association with TNM staging (*P* = 0.018) and HER-2 status (*P* = 0.013). In middle and old age group, BMI classification showed a significant association with tumor status (*P* = 0.001).

Recurrence and survival outcomes of the BMI groups
--------------------------------------------------

Next, we conducted a survival analysis to test how body mass index is related to clinical prognosis (Fig. [2](#F2){ref-type="fig"}A-B). The results showed that DFS and OS were significantly worse for overweight group patients compared with normal group patients (*P* = 0.002 for DFS; *P* = 0.001 for OS). However, compared with normal group patients, it is not obvious an interaction between underweight and DFS or OS (*P* = 0.151 for DFS; *P* = 0.207 for OS). Therefore, we used stratified analysis to explore the impact of underweight on breast cancer patients with different ages (Fig. [2](#F2){ref-type="fig"}C-F). The prognostic significance of OS of underweight were only seen in young age group patients (*P*=0.046). Meanwhile, the results of overweight group are also shown in the Fig. [2](#F2){ref-type="fig"}C-F.

Discussion
==========

Weight problems are rapidly becoming a vital health issue affecting many people in the world [@B17]-[@B19]. Especially the consequences of the epidemic of overweightness or obesity have caused extensive concern amongst common people [@B20]. Research shows that being overweight or obese is linked to a greater risk of some types of cancers including postmenopausal breast, colon, kidney, and esophageal cancers [@B6], [@B21], [@B22]. On the other hand, being underweight is also a problem that can\'t be neglected [@B14]. However, very few analyses of trends in being underweight [@B23], especially for cancer patients, and in severe and morbid obesity have been done. Meanwhile, many researchers included underweight patients in the normal reference group in previous studies [@B24], [@B25]. Compared to overweightness or obesity, underweight does not arouse sufficient attention. In this study, we demonstrated in 3891 Chinese patients that being underweight (BMI\<18.5 kg/m^2^) was associated with adverse outcomes in young patients (under 40 years old) with lymph node metastasis. We noticed that many previously studies excluded IV stage patients. Our study included all stages breast cancer patients which better reveals the real status. About 32% patients face weight problems. It followed a pattern with 25% of patients being either overweight or obese and 7% of patients categorized as being underweight. Meanwhile, we notice that the major weight problem will be different depending on diagnosis age. Underweight is prominent in young age group. While overweight is mainly in middle or old aged patients. This phenomenon might mirror recent trends in the Chinese population. It has been well documented that human race has a significant effect on the peak age of breast cancer [@B26]. The peak age is between 60 and 70 years in Western countries, but is between 40 and 50 years in Asian countries [@B27]. Therefore, we have more premenopausal and young patients. In a German study which involved more than 8,800 breast cancer patients show that only 1.5% (134/8,872) of patients were underweight, while about 50% of patients were overweight or obese[@B28]. Meanwhile, a New Zealand study showed that for 5,458 new breast cancers, BMI was normal (18.5-24.9kg/m^2^) for 32.7%, overweight (25-29.9kg/m^2^) 31.1%, obese (\>30kg/m^2^) 34.9% and 1.3% underweight (\<18.5kg/m^2^) [@B29]. Thus, our results suggested that underweight problem might be more widespread in Asian breast cancer.

By investigating the relationship between clinicopathological parameters and BMI, we found that BMI was significantly associated with age. However, previous studies didn\'t discuss the relationship between clinicopathological parameters and BMI by age. The stratified analysis showed that the results in different ages were not entirely identical. Meanwhile, we did not find the relationship between BMI and distant metastasis, which is consistent with the previous study. A recent study screening 848 primary operable breast cancer patients demonstrated that normal weight (BMI = 18-24.9 kg/m^2^) patients were more likely to present with HER-2+ breast cancer and overweight (BMI = 25-29.9 kg/m^2^) and obese (BMI \> 30 kg/m^2^) patients with TNBC [@B30]. Nevertheless, we failed to found such an association between BMI and breast cancer subtype. The differences results might be due to race, BMI classification criteria, numbers of patients and inclusion criteria. We believe a correlation between HER-2+ and BMI needs more studies to confirm, while we found a statistics significance (P=0.013) in young patients. Because in our study, there were a lot of HER-2 (2+) patients who didn\'t receive FISH to determine the HER-2 statue. Besides, when we focused on underweight, we found the most underweight patients in I-II staging, suggesting that underweight wasn\'t limited in breast cancer end-stage.

A growing body of evidence exists linking BMI to prognostic outcome among female breast cancer patients [@B3], [@B31], [@B32]. In this study, we observed this relationship linking was a little complex. Age, lymph node status and TNM staging could affect it. The results confirmed underweight prognosis value of OS in young age group. Low BMI in young female breast cancer patients with lymph node metastases predict adverse prognosis. For a long time doctors wanted to give patients the best treatment but ignored the nutrition support. So far, there was no large-scale survey data about cancer patient nutrition status. Based on our results, we believe that for underweight young breast cancer patients with lymph node metastasis, we should put more attention on nutrition support in their treatment. Although the biological mechanisms are not fully understood, nutrition support might largely improve the prognosis of this cohort of patients. There are several possible mechanisms may explain the worse prognosis of underweight patients. First, underweight patients have decreased physiologic reserve which may make them more vulnerable to adverse events [@B33]. Second, underweight patients were less tolerant of cancer therapies and at higher risk of procedure-related complications. Finally, some BMI-associated risk factors and comorbidities may be more prevalent in underweight patients such as malnutrition, inflammatory and autoimmune disorders, and multi-organ dysfunction. Malnutrition due to being underweight may compromise immune function and surveillance. But, categories of underweight may include both active healthy patients with an inherited lean body type and undernourished patients. Therefore, the detailed remains to be further explored. There are several limitations including the retrospective nature of our study. First, we didn\'t have data on weight changes. Moreover, all of patients in our study are Chinese and we lacked information on BMI-associated risk factors and comorbidities which might have an influence on clinical outcomes. Finally, the number of underweight patients was relatively small, although our sample size was large.

Conclusions
===========

To our knowledge, this is the first Chinese large single-institution retrospective study to assess the association between prognostic outcome and low BMI among female breast cancer with stage I-IV. Our results indicate that underweight problem might be more widespread in Asian breast cancer and prominent in young age group. There is a clear prognostic value of OS of low BMI at the time of initial diagnoses among young female breast cancer patients with lymph node metastases. While no relationship was found between the recurrence rate and underweight. The role of low BMI in breast cancer might depend on patients\' clinical characteristics such as lymph node status and advanced stage. Supplementary nutrition support might be improving advanced stage underweight young female breast cancer patients\' outcome. Future research is needed to confirm whether underweight is unrelated to breast cancer subtypes.
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![**Clinicopathologic features of BMI groups.** (A). Age-related rate of the 3891 enrolled breast cancer patients. (B). Constituent ratio of patients\' BMI (Underweight (UW; BMI\<18.5 kg/m^2^), normal weight (NW; BMI =18.5-24.9 kg/m^2^) and overweight or obese (OW; BMI≥25 kg/m^2^)). (C). Constituent ratio of patients\' BMI in different age groups.](jcav11p1976g001){#F1}

![**Recurrence and survival outcomes of the BMI groups.** (A). DFS and (B). OS of the 3891 enrolled breast cancer patients. (C). DFS and (D). OS of young breast cancer patients. (E). DFS and (F). OS of middle and old breast cancer patients.](jcav11p1976g002){#F2}

![**DFS and OS in young breast cancer patients.** DFS and OS of young breast cancer patients with (A). lymph node negative and (B). lymph node positive. DFS and OS of young breast cancer patients with (C). TNM stage I-II and (D). TNM stage III-IV. *P* \< 0.05, statistically significant.](jcav11p1976g003){#F3}

###### 

Correlation between BMI and clinicopathological variables of breast cancer patients.

  ---------------------------------------------------------------------------------------------------------------
  Variables                        Cases\      SYSUCC Data Set   P value                                
                                   (n= 3891)                                                            
  -------------------------------- ----------- ----------------- --------- ------ ------- ----- ------- ---------
  Age (years)                                                                                           \<0.001

  \<40                             846         118               46.6%     616    23.3%   112   11.3%   

  ≥40                              3045        135               53.4%     2032   76.7%   878   88.7%   

  Menopause                                                                                             \<0.001

  No                               2380        189               74.7%     1727   65.2%   464   46.9%   

  Yes                              1511        64                25.3%     921    34.8%   526   53.1%   

  Tumor status (T)                                                                                      \<0.001

  T1                               1117        78                30.8%     819    30.9%   220   22.2%   

  T2                               2134        134               53.0%     1419   53.6%   581   58.7%   

  T3                               369         20                7.9%      241    9.1%    108   10.9%   

  T4                               271         21                8.3%      169    6.4%    81    8.2%    

  Axillary lymph node metastasis                                                                        0.364

  No                               1961        135               53.4%     1343   50.7%   483   48.8%   

  Yes                              1930        118               46.6%     1305   49.3%   507   51.2%   

  Distance metastasis (M)                                                                               0.749

  No                               3756        244               96.4%     2560   96.7%   952   96.2%   

  Yes                              135         9                 3.6%      88     3.3%    38    3.8%    

  TNM Staging                                                                                           0.026

  I-II                             2806        185               73.1%     1940   73.3%   681   68.8%   

  III-IV                           1085        68                26.9%     708    26.7%   309   31.2%   

  Histological grade                                                                                    0.043

  G1                               122         7                 2.8%      91     3.4%    24    2.4%    

  G2                               1932        137               54.2%     1333   50.3%   462   46.7%   

  G3                               1837        109               43.1%     1224   46.2%   504   50.9%   

  ER status                                                                                             0.757

  Negative                         1549        105               41.5%     1045   39.5%   399   40.3%   

  Positive                         2264        143               56.5%     1554   58.7%   567   57.3%   

  Unknown                          78          5                 2.0%      49     1.9%    24    2.4%    

  PR status                                                                                             0.630

  Negative                         1471        102               40.3%     987    37.3%   382   38.6%   

  Positive                         2348        146               57.7%     1616   61.0%   586   59.2%   

  Unknown                          72          5                 2.0%      45     1.7%    22    2.2%    

  HER-2 status                                                                                          0.224

  \- or +                          2516        154               60.9%     1720   65.0%   642   64.8%   

  ++                               353         29                11.5%     248    9.4%    76    7.7%    

  +++                              766         50                19.8%     503    19.0%   213   21.5%   

  Unknown                          256         20                7.9%      177    6.7%    59    6.0%    

  Subtype                                                                                               0.397

  Luminal A or B                   2667        169               66.8%     1828   69.0%   670   67.7%   

  HER-2                            425         30                11.9%     273    10.3%   122   12.3%   

  TNBC                             718         48                19.0%     498    18.8%   172   17.4%   

  Unknown                          81          6                 2.4%      49     1.9%    26    2.6%    
  ---------------------------------------------------------------------------------------------------------------

\* P \< 0.05, statistically significant.

###### 

The relationship between BMI groups and clinicopathologic features in different ages groups.

  Variables                        Young   P value   Middle and Old   P value                                                                     
  -------------------------------- ------- --------- ---------------- --------- ----- ------- -------- ----- ------- ------ ------- ----- ------- --------
  Tumor status (T)                                                                            0.168                                               0.001
  T1                               41      34.7%     197              32.0%     24    21.4%            37    27.4%   622    30.6%   196   22.3%   
  T2                               57      48.3%     311              50.5%     61    54.5%            77    57.0%   1108   54.5%   520   59.2%   
  T3                               10      8.5%      70               11.4%     19    17.0%            10    7.4%    171    8.4%    89    10.1%   
  T4                               10      8.5%      38               6.2%      8     7.1%             11    8.1%    131    6.4%    73    8.3%    
  Axillary lymph node metastasis                                                              0.600                                               0.168
  No                               57      48.3%     315              51.1%     52    46.4%            78    57.8%   1028   50.6%   431   49.1%   
  Yes                              61      51.7%     301              48.9%     60    53.6%            57    42.2%   1004   49.4%   447   50.9%   
  Distance metastasis (M)                                                                     0.343a                                              0.374a
  No                               111     94.1%     596              96.8%     108   96.4%            133   98.5%   1964   96.7%   844   96.1%   
  Yes                              7       5.9%      20               3.2%      4     3.6%             2     1.5%    68     3.3%    34    3.9%    
  TNM Staging                                                                                 0.018                                               0.092
  I-II                             82      69.5%     445              72.2%     66    58.9%            103   76.3%   1495   73.6%   615   70.0%   
  III-IV                           36      30.5%     171              27.8%     46    41.1%            32    23.7%   537    26.4%   263   30.0%   
  Histological grade                                                                          0.378a                                              0.101
  G1                               2       1.7%      25               4.1%      2     1.8%             5     3.7%    66     3.2%    22    2.5%    
  G2                               62      52.5%     301              48.9%     49    43.8%            75    55.6%   1032   50.8%   413   47.0%   
  G3                               54      45.8%     290              47.1%     61    54.5%            55    40.7%   934    46.0%   443   50.5%   
  ER status                                                                                   0.275a                                              0.639
  Negative                         47      39.8%     242              39.3%     56    50.0%            58    43.0%   803    39.5%   343   39.1%   
  Positive                         69      58.5%     359              58.3%     53    47.3%            74    54.8%   1195   58.8%   514   58.5%   
  Unknown                          2       1.7%      15               2.4%      3     2.7%             3     2.2%    34     1.7%    21    2.4%    
  PR status                                                                                   0.953a                                              0.595
  Negative                         45      38.1%     218              35.4%     41    36.6%            57    42.2%   769    37.8%   341   38.8%   
  Positive                         71      60.2%     285              46.3%     68    60.7%            75    55.6%   1231   60.6%   518   59.0%   
  Unknown                          2       1.7%      13               2.1%      3     2.7%             3     2.2%    32     1.6%    19    2.2%    
  HER-2 status                                                                                0.013                                               0.304
  \- or +                          74      62.7%     413              67.0%     71    63.4%            80    59.3%   1307   64.3%   571   65.0%   
  ++                               17      14.4%     52               8.4%      2     1.8%             29    21.5%   395    19.4%   185   21.1%   
  +++                              21      17.8%     108              17.5%     28    25.0%            12    8.9%    196    9.6%    74    8.4%    
  Unknown                          6       5.1%      43               7.0%      11    9.8%             14    10.4%   134    6.6%    48    5.5%    
  Subtype                                                                                     0.565                                               0.550
  Luminal A or B                   81      68.6%     419              68.0%     70    62.5%            17    12.6%   221    10.9%   106   12.1%   
  HER-2                            13      11.0%     52               8.4%      16    14.3%            88    65.2%   1409   69.3%   600   68.3%   
  TNBC                             22      18.6%     131              21.3%     23    20.5%            26    19.3%   367    18.1%   149   17.0%   
  Unknown                          2       1.7%      14               2.3%      3     2.7%             4     3.0%    35     1.7%    23    2.6%    

\* P \< 0.05, statistically significant.

a\. using Fisher\'s exact test

###### 

Univariate and Multivariate COX regression analysis for Disease-free Survival and Overall Survival in in young age breast cancer patient group.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                Disease-free Survival   Overall Survival                                                                                             
  ------------------------ ----------------------- ------------------ ---------------------- --------- ----------------------- --------- ---------------------- ---------
  TNM Staging                                                                                                                                                   

  I                        1 (Reference)                              1 (Reference)                    1 (Reference)                     1 (Reference)          

  II                       1.837(0.950-3.552)      0.071              1.525(0.783-2.972)     0.215     2.057(1.038-4.075)      0.039     1.756(0.881-3.503)     0.110

  III                      5.631(2.965-10.695)     \<0.001            3.999(2.071-7.721)     \<0.001   6.263(3.211-12.216)     \<0.001   4.241(2.137-8.418)     \<0.001

  IV                       27.496(13.363-56.575)   \<0.001            15.965(7.477-34.088)   \<0.001   22.081(10.088-48.333)   \<0.001   11.317(4.969-25.777)   \<0.001

  Histological grade                                                                                                                                            

  G1                       1 (Reference)                              1 (Reference)                    1 (Reference)                     1 (Reference)          

  G2                       2.683 (0.368-19.558)    0.330              1.978 (0.268-14.582)   0.503     2.552(0.349-18.651)     0.356     1.853 (0.251-13.704)   0.546

  G3                       8.184 (1.142-58.657)    0.036              3.788 (0.518-27.694)   0.189     8.031(1.120-57.578)     0.038     3.955 (0.541-28.938)   0.176

  ER status\               0.622(0.441-0.876)      0.007              0.809 (0.566-1.155)    0.244     0.605(0.426-0.861)      0.005     0.784(0.484-1.156)     0.191
  (Negative vs Positive)                                                                                                                                        

  PR status\               0.732(0.518-1.036)      0.078              \-                     \-        0.697 (0.489-0.992)     0.045     1.063(0.688-1.642)     0.782
  (Negative vs Positive)                                                                                                                                        

  HER-2 status                                                                                                                                                  

  \- or +                  1 (Reference)                              1 (Reference)                    1 (Reference)                     1 (Reference)          

  ++                       1.018(0.543-1.909)      0.955              0.939 (0.492-1.791)    0.848     0.963 (0.499-1.860)     0.911     0.804 (0.410-1.575)    0.525

  +++                      1.304(1.034-2.276)      0.033              1.124 (0.749-1.686)    0.573     1.604 (1.077-2.388)     0.020     1.185 (0.785-1.788)    0.420

  BMI                                                                                                                                                           

  Normal weight            1 (Reference)                              1 (Reference)                    1 (Reference)                     1 (Reference)          

  Underweight              1.501(0.970-2.324)      0.068              1.467(0.940-2.291)     0.092     1.557(1.003-2.416)      0.048     1.610(1.028-2.523)     0.037

  Overweight               1.676(1.083-2.595)      0.021              1.457(0.931-2.281)     0.099     1.611 (1.024-2.535)     0.039     1.383(0.871-2.196)     0.169
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Statistically significant prognostic factor identified by Univariate/Multivariate analysis
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